替吉奥与氟尿嘧啶治疗中国晚期胃癌患者的Meta分析
发布时间：2018-10-17 22:17
【摘要】：目的比较替吉奥(S-1)与氟尿嘧啶(5-FU)在中国晚期胃癌患者中的有效性及安全性。方法检索中国知网、万方数据及PubMed,查找在中国晚期胃癌患者中应用S-1与5-FU的多中心随机对照试验(mcRCTs),采用RevMan 5.2软件进行Meta分析。结果纳入4个mcRCTs。Meta分析显示S-1可以显著提高客观缓解率[OR=1.90,95%CI(1.36~2.65),P0.01]和疾病控制率[OR=2.08(1.43~3.03),P0.01],但未显示出总生存优势[HR=0.76(0.39~1.50),P=0.82]。S-1组的白细胞减少[1~4级:OR=2.40(1.41~4.07),P0.01;3~4级:OR=3.09(1.94~4.93),P0.01]、中性粒细胞减少[1~4级:OR=2.23(1.60~3.10),P0.01;3~4级:OR=2.90(1.40~6.02),P0.01]、血小板减少[1~4级:OR=2.40(1.56~3.69),P0.01]、贫血[3~4级:OR=1.78(1.11~2.87),P=0.02]及腹泻[3~4级:OR=2.51(1.13~5.58),P=0.02]的发生率均高于5-FU组,而其他的消化系统不良事件发生率相对低于5-FU组,但仅1~4级恶心的发生率显著低于5-FU组[OR=0.59(0.42~0.81),P0.01]。结论对于中国晚期胃癌患者,S-1可以显著提高客观缓解率及疾病控制率,但增加血液系统不良事件及腹泻的发生率;而在生存时间方面虽不劣于5-FU。
[Abstract]:Objective to compare the efficacy and safety of Tegeo (S-1) and fluorouracil (5-FU) in patients with advanced gastric cancer in China. Methods to search China Zhiwang, Wanfang data and PubMed, search for Meta analysis of S-1 and 5-FU multicenter randomized controlled trial (mcRCTs),) using RevMan 5.2 software in patients with advanced gastric cancer in China. 缁撴灉绾冲叆4涓猰cRCTs.Meta鍒嗘瀽鏄剧ずS-1鍙互鏄捐憲鎻愰珮瀹㈣缂撹В鐜嘯OR=1.90,95%CI(1.36~2.65),P0.01]鍜岀柧鐥呮帶鍒剁巼[OR=2.08(1.43~3.03),P0.01],浣嗘湭鏄剧ず鍑烘，
本文编号：2278193
[Abstract]:Objective to compare the efficacy and safety of Tegeo (S-1) and fluorouracil (5-FU) in patients with advanced gastric cancer in China. Methods to search China Zhiwang, Wanfang data and PubMed, search for Meta analysis of S-1 and 5-FU multicenter randomized controlled trial (mcRCTs),) using RevMan 5.2 software in patients with advanced gastric cancer in China. 缁撴灉绾冲叆4涓猰cRCTs.Meta鍒嗘瀽鏄剧ずS-1鍙互鏄捐憲鎻愰珮瀹㈣缂撹В鐜嘯OR=1.90,95%CI(1.36~2.65),P0.01]鍜岀柧鐥呮帶鍒剁巼[OR=2.08(1.43~3.03),P0.01],浣嗘湭鏄剧ず鍑烘，
本文编号：2278193
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2278193.html
